X0202 SCHEDULE 13D/A 0001848809 XXXXXXXX LIVE 3 Voting Common Stock, par value $0.0001 per share 07/16/2026 true 0001788028 471871202 Jasper Therapeutics, Inc.

2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065

Adam Morgan 646-844-0030 Velan Capital Investment Management LP 100 North Main Street, Suite 301 Alpharetta GA 30009 Ryan Nebel 212-451-2300 Olshan Frome Wolosky LLP 1325 Avenue of the Americas New York NY 10019 0001964356 N Velan Capital Master Fund LP WC N E9 0.00 3021915.00 0.00 3021915.00 3021915.00 N 8.9 PN 0001964353 N Velan Capital Holdings LLC AF N DE 0.00 3021915.00 0.00 3021915.00 3021915.00 N 8.9 OO 0002057740 N Velan Horizon Fund LP WC N DE 0.00 82304.00 0.00 82304.00 82304.00 N 0.2 PN 0002057821 N Velan Horizon GP LLC AF N DE 0.00 82304.00 0.00 82304.00 82304.00 N 0.2 OO 0001822834 N Avego Healthcare Capital, L.P. WC OO N DE 0.00 245328.00 0.00 245328.00 245328.00 N 0.7 PN 0001964446 N Avego Healthcare Capital Holdings, LLC AF N DE 0.00 245328.00 0.00 245328.00 245328.00 N 0.7 OO 0001886177 N Avego Management LLC AF N DE 0.00 245328.00 0.00 245328.00 245328.00 N 0.7 OO 0001848809 N Velan Capital Investment Management LP AF N DE 0.00 3349547.00 0.00 3349547.00 3349547.00 N 9.88 PN 0001964355 N Velan Capital Management LLC AF N DE 0.00 3349547.00 0.00 3349547.00 3349547.00 N 9.88 OO 0001964335 N Morgan Adam AF N X1 0.00 3349547.00 0.00 3349547.00 3349547.00 N 9.88 IN 0001114916 N VENKATARAMAN BALAJI AF N X1 0.00 3349547.00 0.00 3349547.00 3349547.00 N 9.88 IN 0001798946 N Kapoor Vishal OO N X1 35013.00 0.00 35013.00 0.00 35013.00 N 0.1 IN Voting Common Stock, par value $0.0001 per share Jasper Therapeutics, Inc. 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 Item 3 is hereby amended and restated to read as follows: The Shares beneficially owned directly by Velan Master were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 2,381,915 Shares beneficially owned by Velan Master is approximately $23,133,322, including brokerage commissions. Velan Master also owns 1,193,415 Warrants (as defined in Amendment No. 2 to the Schedule 13D), which were acquired pursuant to the 2025 Offering (as defined in Amendment No. 2 to the Schedule 13D). The Shares beneficially owned directly by Velan Horizon were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 41,152 Shares beneficially owned by Velan Horizon is approximately $94,855, including brokerage commissions. Velan Horizon also owns 41,152 Warrants, which were acquired pursuant to the 2025 Offering. The Shares beneficially owned directly by Avego Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 245,328 Shares beneficially owned by Avego Fund is approximately $21,512,500, including brokerage commissions. Of the 35,013 Shares beneficially owned directly by Mr. Kapoor, (i) 4,375 Shares were granted to him in connection with the closing of the Business Combination Agreement (as defined in the initial Schedule 13D) in relation to his position as President of Amplitude Healthcare Acquisition Corporation at the time and (ii) 30,638 Shares are issuable upon the exercise of stock options that were awarded to him by the Issuer in connection with his service as a director. Item 4 is hereby amended to add the following: On July 16, 2026, the Issuer acquired Kira Pharmaceuticals ("Kira"), a Cayman Islands exempted company, in accordance with the terms of the Agreement and Plan of Merger, dated July 16, 2026 (the "Merger Agreement"), by and among the Issuer, Kira and Kira Holdco Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"). Pursuant to the Merger Agreement, Kira merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation and a wholly owned subsidiary of the Issuer (the "Merger"). In accordance with the Merger Agreement, on July 16, 2026, Vishal Kapoor notified the Board of his resignation, effective immediately after the Effective Time (as defined in the Merger Agreement). Item 5(a) is hereby amended and restated to read as follows: The aggregate percentage of Shares reported owned by each person named herein is based upon 33,204,811 Shares believed to be outstanding following the Merger, consisting of the (i) 28,009,802 Shares outstanding as of June 5, 2026, which is the total number of Shares outstanding as disclosed in the Issuer's Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 15, 2026, and (ii) 5,195,009 Shares issued following the closing of the Merger pursuant to the Merger Agreement, as disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2026, plus the Shares underlying the Warrants that may be exercisable by the Reporting Persons, as applicable and subject to a 9.99% beneficial ownership blocker provision (the "Ownership Limitation"), and solely with respect to Mr. Kapoor, the Shares issuable upon the exercise of stock options that were awarded to him by the Issuer. As of the date hereof, Velan Master directly beneficially owns 3,021,915 Shares (including 640,000 Shares underlying certain Warrants), constituting approximately 8.9% of the Shares outstanding. Velan GP, as the general partner of Velan Master, may be deemed to beneficially own the 3,021,915 Shares owned by Velan Master, constituting approximately 8.9% of the Shares outstanding. As of the date hereof, Velan Horizon directly beneficially owns 82,304 Shares (including 41,152 Shares underlying certain Warrants), constituting approximately 0.2% of the Shares outstanding. Velan Horizon GP, as the general partner of Velan Horizon, may be deemed to beneficially own the 82,304 Shares owned by Velan Horizon, constituting approximately 0.2% of the Shares outstanding. As of the date hereof, Avego Fund directly beneficially owns 245,328 Shares, constituting approximately 0.7% of the Shares outstanding. Avego GP, as the general partner of Avego Fund, may be deemed to beneficially own the 245,328 Shares beneficially owned by Avego Fund, constituting approximately 0.7% of the Shares outstanding. Avego Management, as the co-investment manager of Avego Fund, may be deemed to beneficially own the 245,328 Shares beneficially owned by Avego Fund, constituting approximately 0.7% of the Shares outstanding. Velan Capital, as the investment manager of each of Velan Master and Velan Horizon and co-investment manager of Avego Fund, may be deemed to beneficially own the 3,349,547 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund, constituting approximately 9.88% of the Shares outstanding. Velan IM GP, as the general partner of Velan Capital, may be deemed to beneficially own the 3,349,547 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund, constituting approximately 9.88% of the Shares outstanding. Mr. Morgan, as the Chief Investment Officer of Velan Capital and a Managing Member of each of Velan GP, Velan Horizon GP and Velan IM GP, may be deemed to beneficially own the 3,349,547 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund, constituting approximately 9.88% of the Shares outstanding. Mr. Venkataraman, as the Managing Member of each of Avego GP and Avego Management and a Managing Member of each of Velan GP, Velan Horizon GP and Velan IM GP, may be deemed to beneficially own the 3,349,547 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund, constituting approximately 9.88% of the Shares outstanding. As of the date hereof, Mr. Kapoor directly beneficially owns 35,013 Shares, including 30,638 Shares underlying certain options, constituting approximately 0.1% of the outstanding Shares. If the Warrants were not subject to the Ownership Limitation, the Reporting Persons would collectively beneficially own an aggregate of 3,937,975 Shares (including 1,234,567 Shares underlying the Warrants and 30,638 Shares underlying certain options), constituting approximately 11.4% of the Shares outstanding. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own. Item 5(c) is hereby amended and restated to read as follows: There have been no transactions in the securities of the Issuer by the Reporting Persons during the past 60 days. Velan Capital Master Fund LP /s/ Adam Morgan 07/20/2026 Velan Capital Holdings LLC /s/ Adam Morgan 07/20/2026 Velan Horizon Fund LP /s/ Adam Morgan 07/20/2026 Velan Horizon GP LLC /s/ Adam Morgan 07/20/2026 Avego Healthcare Capital, L.P. /s/ Balaji Venkataraman 07/20/2026 Avego Healthcare Capital Holdings, LLC /s/ Balaji Venkataraman 07/20/2026 Avego Management LLC /s/ Balaji Venkataraman 07/20/2026 Velan Capital Investment Management LP /s/ Adam Morgan 07/20/2026 Velan Capital Management LLC /s/ Adam Morgan 07/20/2026 Morgan Adam /s/ Adam Morgan 07/20/2026 VENKATARAMAN BALAJI /s/ Balaji Venkataraman 07/20/2026 Kapoor Vishal /s/ Vishal Kapoor 07/20/2026